Skip to content
DataLookout
Menu

UmbREALungNCT06726720

UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Nov 18, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 12 versions: 9 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 7 words
    • Trial sites expanded: 52 → 85 locations
    • Trial sites reduced: 70 → 52 locations
    • Secondary endpoints: details revised at 10 of 14 entries
  2. Minor Trial sites expanded: 52 → 70 locationsv11
  3. Minor Study sites: 40 to 52v9
  4. Minor Study sites: 39 to 40v7
  5. Minor Study sites: 28 to 39v6
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites: 21 to 28v4
  2. Minor Study sites: 2 to 21v3
  3. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoints: 3 to 4
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 11, 2024 to Dec 16, 2024
    • Secondary endpoints: 1 to 14
    • Study title expanded, about 2 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohort A (resectable NSCLC)-Adjuvant rw DFS
Timeframe: 3 years
Cohort A (resectable NSCLC)- Peri-operative rw EFS
Timeframe: 3 years
Cohort B (unresectable NSCLC): median rwTFST
Timeframe: 3 years
Cohort C (metastatic NSCLC) rw TFST
Timeframe: 3 years

Secondary (14)

Response rates - all cohorts
Additional rw EFS (cohort A - Peri-operative)
Additional rwDFS (Cohort A- adjuvant)
rwPFS (cohort B and C)
Early progressors-rates and characteristics of patients - all cohorts
Show 9 moreShow less
rwPFS2 (all cohorts)
rwD-RFS or rwD-PFS ( cohort A and B)
Real-word locoregional recurrence-free survival (rwL-RFS) - cohort A and B
rwOS - all cohorts
Real world time to treatment discontinuation (rwTTD) - all cohorts
Real world time to next treatment (rwTTNT) - all cohorts
Real world time to first subsequent local treatment (rwTFST-local treatment) all cohorts
rwTFST (systemic) - cohort A and B
Description of associated therapies

Arms and interventions

Cohort 1 - Resectable

Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in resectable NSCLC

Cohort 2 - Unresectable

Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in Unresectable NSCLC

Cohort 3 - Metastatic

Ambispective, observational, study of patients with non-small cell lung cancer initiating approved drugs developed by AZ or as part of an AZ alliance in Metastatic NSCLC

Sites

85 sites in 2 countries

France 55, Germany 30